Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
famitinib vascular endothelial growth factor receptor 1 NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.21 phase 2 inhibitor
famitinib vascular endothelial growth factor receptor 1 NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.21 phase 2 unknown
famitinib fms-like tyrosine kinase 3 NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.19 phase 2 inhibitor
famitinib fms-like tyrosine kinase 3 NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.19 phase 2 unknown
famitinib vascular endothelial growth factor receptor 3 NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.21 phase 2 inhibitor
famitinib vascular endothelial growth factor receptor 3 NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.21 phase 2 unknown
famitinib vascular endothelial growth factor receptor 2 NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.2 phase 2 unknown
famitinib vascular endothelial growth factor receptor 2 NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.2 phase 2 inhibitor
famitinib tyrosine-protein kinase kit NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.38 phase 2 inhibitor
famitinib tyrosine-protein kinase kit NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.38 phase 2 unknown
famitinib platelet-derived growth factor receptor alpha NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.28 phase 2 unknown
famitinib platelet-derived growth factor receptor alpha NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.28 phase 2 inhibitor
famitinib platelet-derived growth factor receptor beta NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.35 phase 2 unknown
famitinib platelet-derived growth factor receptor beta NA Successful target TTD , DGIDB Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Malignant Neoplasms[MeSHID:D009369]		 0.35 phase 2 inhibitor
click here to return to the previous page